Generalized lymphatic anomaly successfully treated with long-term, low-dose sirolimus

Generalized lymphatic anomaly is a rare, complex, lymphatic anomaly generally involving soft tissues, spleen, and bones. It can lead to focal skeletal fragility and pathologic effusions. A recent prospective trial of sirolimus for complicated vascular anomalies showed partial response in seven patients with generalized lymphatic anomaly treated with sirolimus with a target trough level of 10-15ng/mL for 1year (Adams etal). We describe successful treatment of generalized lymphatic anomaly with a lower-dose, long-term course of sirolimus.